Repligen：收購案將增強細胞治療能力 (NASDAQ:RGEN)
· seekingalpha.com
Repligen 以 15 億美元收購 BioLife 以及強勁的第二季財報推升了財務指引，但估值似乎過高。點擊查看更多關於 RGEN 股票的資訊。
If you like to see more ideas, please subscribe to the Investing Group "Value in Corporate Events" here and try the free trial. In this service we cover major e...